Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.4 EUR | 0.00% | +3.33% | +13.76% |
05-02 | Magis announces warrant exercise ratio for May | AN |
03-26 | Magis improves profit in 2023; revenues down 14 percent | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 8.77 and 8.23 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.65 for the 2023 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.76% | 59.96M | - | ||
+16.03% | 35.68B | B+ | ||
+0.84% | 4.42B | B+ | ||
+40.21% | 1.44B | - | - | |
+18.36% | 1.42B | D | ||
-0.96% | 1.36B | - | - | |
-22.13% | 790M | - | - | |
-24.75% | 780M | - | ||
-15.51% | 717M | - | ||
-39.47% | 630M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MGS Stock
- Ratings Magis S.p.A.